GLP-1 Weight Loss & Diabetes Global Duopoly
LLY vs NVO: Head-to-Head Comparison
Comparing quantitative economic moats, Forward P/E multiples, balance sheet liquidity, and institutional 13F whale conviction.
👑 Higher Moat Score
LLY
LLY 🇺🇸
Eli Lilly and Company
$1115.7
-0.65%
MOAT SCORE
⚡ 87.0/100
VS
📊 Quantitative Fundamental Matchup
| Fundamental Metric | LLY (Eli Lilly and Company) | NVO (Novo Nordisk A/S) | Advantage |
|---|---|---|---|
| Moat Score™ (0-100) | ⚡ 87.0 | ⚡ 83.0 | LLY (+4.0 pts) |
| Market Capitalization | $994.9B | $190.3B | - |
| Forward P/E Ratio | 30.4x | 1.9x | NVO (Cheaper Multiple) |
| Trailing P/E Ratio | 37.5x | 10.5x | - |
| Gross Profit Margin | 83.4% | 82.0% | LLY (Higher Pricing Power) |
| YoY Revenue Growth | +47.7% | +2.1% | LLY |
| Free Cash Flow | $11.1B | $37.7B | - |
| Superinvestor 13F Backing | None Tracked | None Tracked | NVO |
🏆 The MoatPicks Verdict: LLY Wins on Fundamentals
Based on our 12-point quantitative audit, LLY (Eli Lilly and Company) achieves an overall Moat Score of 87.0/100 compared to 83.0/100 for NVO. LLY demonstrates superior capital allocation efficiency and wider defensive moat characteristics in the Healthcare sector.
Find All 100+ Top-Ranked Moat Compounders
Get real-time 3-hour price updates, 13F whale transaction alerts, and complete 12-point fundamental breakdowns.
Unlock MoatPicks PRO →